Clinical Trials
51 trialsBCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
DP-04
AstraZeneca
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
NEXUS-01
Eli Lilly and Company
LEARN
University of Sydney
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
ReRT
The New York Proton Center
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
MOMENTUM
UMC Utrecht
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
GUARDIAN-101
Clasp Therapeutics, Inc.
PharmTRT
Hospices Civils de Lyon
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
TAGNOT
Kidney Cancer Research Bureau
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
P-MRI
University of Michigan
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
PETRiS
XEOS Medical
DETERMINE
Cancer Research UK
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
FASCINATE
The Netherlands Cancer Institute
JUMP
Brigham and Women's Hospital
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
National Cancer Centre, Singapore
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
Algemeen Ziekenhuis Maria Middelares
MOHCCN-O
University Health Network, Toronto
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
COACH
Pack Health
Survivorship
University of Modena and Reggio Emilia
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
Assiut University
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
University College, London
KEYNOTE F19
Evopoint Biosciences Inc.
ISRAR
Hospices Civils de Lyon
Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers
Sunnybrook Health Sciences Centre
ART-02
Charite University, Berlin, Germany
EXCEL
University of Calgary
ONCOPRO
Hospices Civils de Lyon